<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4309">
  <stage>Registered</stage>
  <submitdate>19/02/2014</submitdate>
  <approvaldate>19/02/2014</approvaldate>
  <nctid>NCT02068352</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis</studytitle>
    <scientifictitle>A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>271-12-205</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atopic Dermatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - OPA-15406
Treatment: drugs - Placebo

Experimental: 0.3% OPA-15406 - BID 0.3% OPA-15406 Ointment, N = 40

Experimental: 1% OPA-15406 - BID 1% OPA-15406 Ointment, N = 40

Placebo Comparator: Placebo - BID 0% Vehicle Ointment, N = 40


Treatment: drugs: OPA-15406
0.3% or 1% OPA-15406 topical ointment, applied twice daily for 8 weeks

Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as assessed by incidence and severity of adverse events.</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of success (as defined by a score of 0 (clear) or 1 (almost clear) with at least a 2 grade reduction from Baseline) in the overall IGA score at Week 4 for OPA 15406 concentrations vs. vehicle.</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of success in the overall IGA score at Week 8 for OPA 15406 concentrations vs. vehicle.</outcome>
      <timepoint>56 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects 10-70 years of age

          -  Diagnosis of atopic dermatitis (AD)

          -  History of AD for at least 3 years

          -  AD affecting greater than or equal to 5% and less than or equal to 40% of total Body
             Surface Area (BSA) at Baseline

          -  Investigator's Global Assessment of Disease Severity score of 2 (mild) or 3 (moderate)
             in the selected treatment area(s)</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Contact or atopic dermatitis flare within 28 days of the Baseline (Day 1) visit.

          -  Concurrent diseases/conditions and history of other diseases/conditions in the
             selected treatment areas(s) that may have an impact on the study assessments.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>94</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,WA</recruitmentstate>
    <hospital> - Phillip</hospital>
    <hospital> - Kogarah</hospital>
    <hospital> - Woolloongabba</hospital>
    <hospital> - Hectorville</hospital>
    <hospital> - Fremantle</hospital>
    <postcode> - Phillip</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode>5073 - Hectorville</postcode>
    <postcode> - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the effectiveness and safety of 2 concentrations
      of OPA-15406 compared to vehicle in subjects with atopic dermatitis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02068352</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>